SEC Form SC 13G/A filed by Onconetix Inc. (Amendment)

$ONCO
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $ONCO alert in real time by email
SC 13G/A 1 ea0207523-13ga1hernan_oncon.htm AMENDMENT NO. 1 TO SCHEDULE 13G

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

SCHEDULE 13G

(Amendment No. 1)*

 

Under the Securities Exchange Act of 1934

 

Onconetix, Inc.

(Name of Issuer)

 

Common Stock, par value $0.00001 per share

(Titles of Class of Securities)

 

09610B 108

(CUSIP Number)

 

June 6, 2024

(Date of Event Which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

Rule 13d-1(b)

 

Rule 13d-1(c)

 

Rule 13d-1(d)

 

*The remainder of this cover page shall be filled out of a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

 

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

 

 

 

1

NAME OF REPORTING PERSON

 

Joseph Hernandez

2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

 

(a)

(b)

3

SEC USE ONLY

 

4

CITIZENSHIP OR PLACE OF ORGANIZATION

 

United States

NUMBER OF
SHARES

BENEFICIALLY

OWNED BY

EACH
REPORTING PERSON
WITH:

5

SOLE VOTING POWER

 

0

6

SHARED VOTING POWER

 

0

7

SOLE DISPOSITIVE POWER

 

0

8

SHARED DISPOSITIVE POWER

 

0

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

0

10

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

 

11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

 

0%

12

TYPE OF REPORTING PERSON

 

IN

 

2

 

 

Item 1(a).  Name of Issuer:

 

Onconetix, Inc.

 

Item 1(b). Address of Issuer’s Principal Executive Offices:

 

201 E. Fifth Street, Suite 1900

Cincinnati, Ohio 45202

 

Item 2(a). Name of Person Filing

 

Joseph Hernandez (the “Reporting Person”)

 

Item 2(b). Address of Principal Business Office or, if none, Residence

 

The principal business address of the Reporting Person is:

15 East Putnam Avenue

Greenwich, CT 06830

 

Item 2(c). Citizenship

 

United States of America

 

Item 2(d). Title of Class of Securities

 

Common Stock, par value $0.00001 per share

 

Item 2(e). CUSIP Number

 

09610B108

 

Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

 

  (a) Broker or dealer registered under Section 15 of the Exchange Act (15 U.S.C. 78o).
       
  (b) Bank as defined in Section 3(a)(6) of the Exchange Act (15 U.S.C. 78c).
       
  (c) Insurance company as defined in Section 3(a)(19) of the Exchange Act (15 U.S.C. 78c).
       
  (d) Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
       
  (e) Investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).
       
  (f) Employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F).
       
  (g) Parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G).
       
  (h) Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).
       
  (i) Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).
       
  (j) Non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J).
       
  (k) Group in accordance with §240.13d-1(b)(1)(ii)(K).

 

If filing as a non-U.S. institution in accordance with §240. 13d-1(b)(1)(ii)(J), please specify the type of institution: ______________ .

 

3

 

 

Item 4. Ownership

 

  (a) Amount beneficially owned:

 

See Item 9 on the cover page hereto.

 

  (b) Percent of class:

 

See Item 11 on the cover page hereto.

 

  (c) Number of shares as to which such person has:

 

(i)Sole power to vote or to direct the vote:

 

See response to Item 5 on the cover page hereto.

 

(ii)Shared power to vote or to direct the vote:

 

See response to Item 6 on the cover page hereto.

 

(iii)Sole power to dispose or to direct the disposition of:

 

See response to Item 7 on the cover page hereto.

 

(iv)Shared power to dispose or to direct the disposition of:

 

See response to Item 8 on the cover page hereto.

 

Item 5. Ownership of Five Percent or Less of a Class.

 

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following .

 

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

 

Not applicable.

 

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

 

Not Applicable.

 

Item 8. Identification and Classification of Members of the Group.

 

Not Applicable.

 

Item 9. Notice of Dissolution of Group

 

Not Applicable.

 

Item 10. Certification

 

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

 

4

 

 

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Dated: June 7, 2024  
   
  /s/ Joseph Hernandez
  Name: Joseph Hernandez

 

Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations

(See 18 U.S.C. 1001)

 

5

 

Get the next $ONCO alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ONCO

DatePrice TargetRatingAnalyst
More analyst ratings

$ONCO
Press Releases

Fastest customizable press release news feed in the world

See more
  • Onconetix Announces Successful Clinical Validation of its Innovative Prostate Cancer Test Proclarix in a Danish cohort

    CINCINNATI, March 24, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc., (NASDAQ:ONCO) ("Onconetix" or the "Company"), (formerly Blue Water Biotech, Inc. (BWV)), a cancer diagnostics company focused on the research, development and commercialization of innovative solutions for oncology, today announced that new clinical data of Proclarix® was presented on March 23, 2025 during the 2025 European Association of Urology (EAU) congress, which data further demonstrates the strong clinical performance of Proclarix® in a Danish cohort. The primary approach for early detection of prostate cancer is through testing serum levels of prostate-specific antigen (PSA). However, given the limited cancer specific

    $ONCO
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Onconetix Announces New Clinical Data for its Innovative Prostate Cancer Test Proclarix Accepted for Presentation at 2025 European Association of Urology Congress

    CINCINNATI, March 19, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc., (NASDAQ:ONCO) ("Onconetix" or the "Company"), (formerly Blue Water Biotech, Inc. (BWV)), a cancer diagnostics company focused on the research, development and commercialization of innovative solutions for oncology, today announced that an abstract has been accepted for presentation at the 2025 European Association of Urology (EAU) congress taking place March 21-24, 2025, in Madrid, Spain. The presentation, titled, "Clinical Performance of Proclarix in Ruling Out Clinically Insignificant or No Prostate Cancer: Evaluation in a Danish Cohort," will highlight Proclarix performance results recently obtained from a study including

    $ONCO
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Onconetix, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q and Subsequent Filing

    Cincinnati, OH, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ:ONCO) (the "Company") announced that it received a letter from The Nasdaq Capital Market ("Nasdaq") on December 6, 2024 indicating that the Company's failure to file its Quarterly Report on Form 10-Q for the period ended September 30, 2024 (the "Form 10-Q") is in violation of Nasdaq's continued listing requirements under Nasdaq Listing Rule 5250(c)(1) (the "Rule"). On December 10, 2024, the Company filed the Form 10-Q with the Securities and Exchange Commission.   This announcement is made in compliance with Nasdaq Listing Rule 5810(b), which requires prompt disclosure of receipt of a deficiency notification.   Ab

    $ONCO
    Biotechnology: Pharmaceutical Preparations
    Health Care

$ONCO
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$ONCO
SEC Filings

See more

$ONCO
Leadership Updates

Live Leadership Updates

See more
  • Virometix appoints Christina Ackermann as Chair and Tim Ramdeen as member of the Board

    Virometix AG, a privately held Swiss biotechnology company developing a new generation of fully synthetic vaccines to generate targeted and protective immune responses against infectious diseases and cancer today announces the appointment of Christina Ackermann as Chairwoman and Tim Ramdeen as a new member of its Board of Directors. Ms. Ackermann brings over 27 years of legal and management experience within the healthcare industries. Mr. Ramdeen has nearly a decade of experience in private equity, hedge fund investing, and capital markets. Christina Ackermann and Tim Ramdeen have led clinical and commercial companies through product development, growth, and commercialization while raising

    $ENTO
    $OCS
    $ONCO
    $VRNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

$ONCO
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more